In order to accurately grasp the actual development situation of the medical and health industry in the province and assist in improving the quality and efficiency of the industry as well as promoting innovative development, on July 31st, Wang Zongmin, the chairman of the Working Committee of the Medical and Health Industry Alliance of Jiangsu Health Industry Research Association, led a team of experts to visit Nanjing Leecan Pharmaceutical for research and exchange. The founder and chairman of Leecan Pharmaceutical accompanied the research and exchange.

      During the symposium and exchange session, the chairman of Leecan Pharmaceutical comprehensively introduced the company's entrepreneurial aspirations, development history, pipeline layout, and strategic planning. He stated that Leecan Pharmaceutical has always been deeply engaged in niche markets such as high-end inhalation preparations, focusing on unmet clinical needs, continuously tackling and breaking through core technological barriers, and striving to provide patients with safer and higher-quality medication options. Wang Zongmin highly recognized Leecan Pharmaceutical's layout in core markets with high value and high barriers such as high-end inhalation preparations. The company's technological breakthroughs and innovative layouts have effectively filled the shortcomings of the high-end inhalation preparation industry in the province, and have played an important role in promoting the high-quality development of the regional health industry.

      Subsequently, the expert team conducted on-site investigations at the research institute's laboratories, GMP production workshops, and QC laboratories, gaining a detailed understanding of the company's R&D project progress, production line operation mode, and precision equipment advantages. The expert team highly praised Leecan Pharmaceutical for its advanced hardware and software facilities, standardized R&D and production processes, and standardized quality system, highlighting the innovative strength and industrial vitality of Jiangsu's biomedical enterprises.

      This research has built an efficient bridge for collaborative development between the industry platform and enterprises. During the research, the expert group stated that they will provide empowering support in areas such as technical exchange and cooperation, joint research projects, and policy project applications, to assist enterprises in solving development challenges. Leecan Pharmaceutical will leverage the advantageous resources of the alliance platform, continuously refine innovative products, establish a robust full-process quality control system, promote industrial upgrading through core technological breakthroughs, safeguard people's health with high-quality products, and continue to contribute to the high-quality and innovative development of regional industries.